Mercoledì 22 Marzo 2023,
ore 13 Edificio Asclepio U8-Aula 7
Seminario in presenza con possibilità di collegamento da remoto: ► webex Arcangeli
Despite advances in surgery, radical cystectomy remains mutilating, especially if orthotopic neobladder reconstruction is not feasible (> 50% of the cases), and thus negatively impacting quality of life.
Furthermore, surgery is not an option in almost 50% of patients due to age and comorbidities. For such patients, trimodal treatment via transurethral maximal resection of the bladder (TURBT) followed by concomitant chemoradiation has emerged in recent years as a valid therapeutic alternative. Five-year control rates with bladder sparing associated with this strategy have been reported in the range of 40 to 65%, depending on the stage, leading to a 5-y OS rates of 40 to 50%, with excellent quality of life [9–22]. These results appear comparable to surgery.
Therefore, conservative trimodal therapy may be offered in highly selective and operable patients, i.e. patients with limited cT2 and unifocal tumours, without hydronephrosis or carcinoma in situ, with macroscopically complete resection of the lesion prior to initiation of concomitant chemoradiation. Radiotherapy may be also indicated for symptomatic or haemostatic purposes in case of metastatic or locally advanced tumours without the option of curative treatment (pain, haematuria, etc.), as well as in case of pelvic recurrence, either local and/or nodal.
Stefano Arcangeli is:
⁃ Associate Professor of Radiation Oncology at University of Milan Bicocca
⁃ Director of Radiation Oncology Residency Program at University of Milan Bicocca
⁃ Head of Radiation Oncology Department at Fondazione IRCCS San Gerardo dei Tintori.
He has published several articles (indexed/peer-reviewed journals) and bookchapters. Main
topics of his activity are: uro-oncology, radiation oncology, clinical radiobiology. He takes part
as Associate Editor for the following journals: CANCER MEDICINE (Wiley Online Library);
Impact factor:4.452; RADIATION ONCOLOGY (BioMed Central Ltd.); Impact factor:4.309; and
LA RADIOLOGIA MEDICA (Springer); Impact factor: 6.313. He’s an ESTRO (European Society
of Radiation Oncology) and AIRO (Italian Association of Radiotherapy and Clinical Oncology)